These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 38997780)

  • 1. Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes.
    Xiao L; Li Y; Hong C; Ma P; Zhu H; Cui H; Zou X; Wang J; Li R; He J; Liang S; Li Z; Zeng L; Liu L
    J Transl Med; 2024 Jul; 22(1):650. PubMed ID: 38997780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
    Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single nucleus RNA-sequencing integrated into risk variant colocalization discovers 17 cell-type-specific abdominal obesity genes for metabolic dysfunction-associated steatotic liver disease.
    Lee SHT; Garske KM; Arasu UT; Kar A; Miao Z; Alvarez M; Koka A; Darci-Maher N; Benhammou JN; Pan DZ; Örd T; Kaminska D; Männistö V; Heinonen S; Wabitsch M; Laakso M; Agopian VG; Pisegna JR; Pietiläinen KH; Pihlajamäki J; Kaikkonen MU; Pajukanta P
    EBioMedicine; 2024 Aug; 106():105232. PubMed ID: 38991381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interplay of Mediterranean-diet adherence, genetic factors, and metabolic dysfunction-associated steatotic liver disease risk in Korea.
    Kwon YJ; Choi JE; Hong KW; Lee JW
    J Transl Med; 2024 Jun; 22(1):591. PubMed ID: 38918799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.
    Kim D; Wijarnpreecha K; Cholankeril G; Ahmed A
    Aliment Pharmacol Ther; 2024 Jul; 60(1):33-42. PubMed ID: 38649335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between serum ferritin baselines and trajectories and the incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.
    Song Z; Miao X; Xie X; Tang G; Deng J; Hu M; Liu S; Leng S
    Lipids Health Dis; 2024 May; 23(1):141. PubMed ID: 38760825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
    Bianco C; Jamialahmadi O; Pelusi S; Baselli G; Dongiovanni P; Zanoni I; Santoro L; Maier S; Liguori A; Meroni M; Borroni V; D'Ambrosio R; Spagnuolo R; Alisi A; Federico A; Bugianesi E; Petta S; Miele L; Vespasiani-Gentilucci U; Anstee QM; Stickel F; Hampe J; Fischer J; Berg T; Fracanzani AL; Soardo G; Reeves H; Prati D; Romeo S; Valenti L
    J Hepatol; 2021 Apr; 74(4):775-782. PubMed ID: 33248170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study.
    Han E; Lee BW; Kang ES; Cha BS; Ahn SH; Lee YH; Kim SU
    Metabolism; 2024 Mar; 152():155789. PubMed ID: 38224909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease.
    Chen Q; Hu P; Hou X; Sun Y; Jiao M; Peng L; Dai Z; Yin X; Liu R; Li Y; Zhu C
    Cardiovasc Diabetol; 2024 Jul; 23(1):232. PubMed ID: 38965572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Associations between Healthy Eating Patterns and Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Case-Control Study.
    Huang X; Gan D; Fan Y; Fu Q; He C; Liu W; Li F; Ma L; Wang M; Zhang W
    Nutrients; 2024 Jun; 16(12):. PubMed ID: 38931312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of
    Elmansoury N; Megahed AA; Kamal A; El-Nikhely N; Labane M; Abdelmageed M; Daly AK; Wahid A
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus.
    Lavrado NC; Salles GF; Cardoso CRL; de França PHC; Melo MFDGG; Leite NC; Villela-Nogueira CA
    Liver Int; 2024 Apr; 44(4):1042-1050. PubMed ID: 38293718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry.
    Schwantes-An TH; Whitfield JB; Aithal GP; Atkinson SR; Bataller R; Botwin G; Chalasani NP; Cordell HJ; Daly AK; Darlay R; Day CP; Eyer F; Foroud T; Gawrieh S; Gleeson D; Goldman D; Haber PS; Jacquet JM; Lammert CS; Liang T; Liangpunsakul S; Masson S; Mathurin P; Moirand R; McQuillin A; Moreno C; Morgan MY; Mueller S; Müllhaupt B; Nagy LE; Nahon P; Nalpas B; Naveau S; Perney P; Pirmohamed M; Seitz HK; Soyka M; Stickel F; Thompson A; Thursz MR; Trépo E; Morgan TR; Seth D;
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38727677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction-associated steatotic liver disease.
    Kaplan DE; Teerlink CC; Schwantes-An TH; Norden-Krichmar TM; DuVall SL; Morgan TR; Tsao PS; Voight BF; Lynch JA; Vujković M; Chang KM
    Hepatol Commun; 2024 Jul; 8(7):. PubMed ID: 38967582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
    Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.
    Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S
    Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
    Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
    Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.